Abstract:Abstract Abstract 2337 The nucleosome remodeling and deacetylase (NuRD) complex is involved in gene repression and normal hematopoiesis. In embryonic stem (ES) cells, NuRD complex directly maintains the self-renewal from lineage commitment. Murine models with defects in NuRD complex present with increased hematopoietic stem/progenitor cells (HSPCs). Several transcriptional factors (TFs), such as SALL4, FOG1, BCL11A, BCL11B, ZNF521 use a conservative 12 amino acid domain to recruit NuRD components for targeted gene repression. In this study, we plan to test the hypothesis that by blocking the interaction between NuRD and its TFs, we can phenocopy its knockdown effects on human HSPC. Human cord blood (CB) CD34+ cells were purified, and treated with peptide with the NuRD interacting sequences (wt-pep) or its controls mutant peptide (mut-pep) or scramble peptide (scr-pep). In vitro and in vivo assays were performed to evaluate whether wt-pep treatment can maintain or expand human cord blood HSPCs, which were further characterized as CD34+CD90+ and CD34+CD38-CD90+ sub-population with known repopulating potential after ex vivo culture. First we observed wt-pep treated CB CD34+ (1×104) cultures with cytokines (SCF, Flt3 ligand, IL-3 and IL-6) yielded 10.6 times greater numbers of CD34+CD90+ cells (Fig 1) and 19.3 times greater numbers of CD34+CD38-CD90+ as compared to the cultures containing cytokines with scr-pep after 6 days of culture (p<0.05). Colony formation assay demonstrated wt-pep treated cells gave mainly rise to large colonies, while scr-pep treated cells generated high proportion of small colonies, 8 days after plating (p<0.05). Treatment of CB CD34+ cells with wt-pep resulted in an increase in total colony-forming cell (CFC) content compared to other control groups, 14 days after plating (p<0.005). Then, to determine the most contributed to populations, Lin-CD34+CD38+CD90±, Lin-CD34+CD38-CD90± populations were fractionally sorted and treated with wt-pep. While the expansion rate of Lin-CD34+CD38+CD90± were too low to evaluate, wt-pep treated Lin-CD34+CD38-CD90+ and Lin-CD34+CD38-CD90- cells gave rise to 79.3% and 52.7% of CD34+CD90+ cells, respectively. In addition, Lin-CD34+CD38-CD90 + cells gave rise to much more CD34+CD38- population in wt-peptide treated cells as compared with scr-peptide treated cells (44.0%, 16.2% respectively) and almost all of these cells co-expressed CD90. These data suggested that both Lin-CD34+CD38-CD90± cells treated with wt-peptide could give rise to CD34+CD90+ as well as CD34+CD38-CD90+ cells. In addition, CD34+CD38-CD90+ cells seemed more contributed than CD34+CD38-CD90- cells for expansion of CD34+38-CD90+ cells. Based on in vitro experiment results, we investigated immunodeficient (SCID) repopulating activity (SRA) to determine efficacy of wt-pep to HSPCs in vivo. We observed that mice transplanted the progeny of 1×104 CB CD34+ cells treated with wt-pep (n=5) had higher degree of human cell chimerism (0.38%) than that with scr-peptide (0%) (n=5) at 4 weeks in peripheral blood. The 8 weeks chimerism of wt-peptide treated progeny (13.6%; n=5) were greater than scr-peptide treated progeny (1.88%; n=5) (Fig 2; p < 0.005) and also greater than unmanipulated CD34+ cells (1×104) (0.09%; n=3) (Fig 2; p < 0.05). In addition, these mice (n=5) demonstrated that multilineage differentiation. We further analyzed transcription levels of several HSPC related genes, which were compared between CB CD34+ cells treated with wt-peptide and scramble peptide. Significantly higher transcript levels were detected for HoxB4 (p < 0.05), GATA 2 (p < 0.05) and Evi1 (p < 0.05) and lower levels were detected for PTEN (p < 0.05) by real time quantitative RT-PCR in wt-peptide expanded cells as compared with scr-pep cultures. Unlike embryonic stem cells, human HSPC can not be maintained ex vivo in a culture condition. The limit in source cells has greatly hampered the field of HSPC research. Optimizing ex vivo HSPC expansion culture condition not only can facilitate basic research on these cells, but also can be translated into clinical applications such as enhancement of CB engraftment and gene therapy. Our study demonstrates a novel peptide approach for ex vivo expansion of a unique CD34+CD90+ and CD34+CD38-CD90+ population with increased engraftment potential. Future studies will reveal whether the same condition can beapplied to HSPC culture for gene therapy. Disclosures: No relevant conflicts of interest to declare.

Functional Cloning of IGFBP-3 from Human Microvascular Endothelial Cells Reveals Its Novel Role in Promoting Proliferation of Primitive CD34+CD38− Hematopoietic Cells in Vitro

In Vitro and in Vivo Angiogenic Capacity Analysis on Different Clonal Endothelial Progenitor Cell Populations Derived from Human Circulating Blood

Maintenance And Expansion Of Hematopoietic Stem/Progenitor Cells In A Biomimetic Hematopoietic Cells Niche

Efficient Derivation of Human Embryonic Stem Cell Lines from Discarded Embryos Through Increases in the Concentration of Basic Fibroblast Growth Factor

Enhanced HSC-like Cell Generation from Mouse Pluripotent Stem Cells in a 3D Induction System Cocultured with Stromal Cells

[Cord Blood Plasma Selectively Stimulates the Expansion of Hematopoietic Pregenitor Cells in Vitro].

A novel human pluripotent stem cell-based gene activation system identifies IGFBP2 as a mediator in the production of hematopoietic progenitors in vitro

Introduction of OCT4 into Human Bone-Marrow Derived Mesenchymal Stromal Cells Generates Putative Ips Cells with the Potential to Differentiate into CD34+ Hematopoietic Progenitor Cells Ex Vivo

A Novel Approach in Expanding CD34+CD90+ and CD34+CD38-CD90+ Cells Associated with Enhanced in Vivo Repopulating Potential.

Single OCT4 gene introduced into human bone-marrow derived mesenchymal stromal cells can generate putative iPS cells with the potential to differentiate into CD34+ hematopoietic progenitor cells ex vivo

Support of hMSCs transduced with TPO/FL genes to expansion of umbilical cord CD34 + cells in indirect co-culture

Cocultivation of Umbilical Cord Blood CD34+cells with Retro-Transduced Hmscs Leads to Effective Amplification of Long-Term Culture-Initiating Cells

Ex Vivo Expansion and Transplantation of Hematopoietic Stem/progenitor Cells Supported by Mesenchymal Stem Cells from Human Umbilical Cord Blood.

Efficient commitment to functional CD34+ progenitor cells from human bone marrow mesenchymal stem-cell-derived induced pluripotent stem cells

Efficient Induction of CD34+ Progenitor Cells from Human Bone Marrow Mesenchymal Stem Cell-Derived Induced Pluripotent Stem Cells with Defined Chemicals

Transient Disruption of Autocrine Tgf-Beta Signaling Leads to Enhanced Survival and Proliferation Potential in Single Primitive Human Hemopoietic Progenitor Cells

TGFβ inhibition enhances the generation of hematopoietic progenitors from human ES cell-derived hemogenic endothelial cells using a stepwise strategy

A Novel High-Throughput Screening Platform Reveals an Optimized Cytokine Formulation for Human Hematopoietic Progenitor Cell Expansion.

Identification of growth factor conditions that reduce ex vivo cord blood progenitor expansion but do not alter human repopulating cell function in vivo

Biphasic Modulation of Insulin Signaling Enables Highly Efficient Hematopoietic Differentiation from Human Pluripotent Stem Cells.

A Synthetic Three-Dimensional Niche System Facilitates Generation of Functional Hematopoietic Cells from Human-Induced Pluripotent Stem Cells